Tags : In-License

Biocon Biologics Signs an In-License Agreement with Just – Evotec

Shots: Biocon Biologics will perform all end-to-end development activities, IND filing, manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just – Evotec Biologics’ expertise in process development domain mainly in optimized manufacturability Just – Evotec Biologics to receive license fee plus development, regulatory and commercial milestone payments. […]Read More

Oncology Venture Signs an Exclusive Option Agreement to In-License Commercialization

Shots: Oncology to evaluate Ixempra (ixabepilone) in combination with DRP CDx for metastatic breast cancer in EU. Post the results of trial, Oncology has an exclusive option to in-license commercialization rights for Ixempra in EU The focus of the in-licensing agreement is to utilize Oncology Ventures’ Drug Response Prediction (DRP) biomarker platform for the enhancement […]Read More